Virax Biolabs Group (VRAX) Competitors $0.62 -0.01 (-1.32%) Closing price 04:00 PM EasternExtended Trading$0.61 -0.01 (-1.13%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. HOOK, PHXM, ALBT, IMCC, PCSA, VIVS, ADXN, APM, BCDA, and RNAZShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include HOOKIPA Pharma (HOOK), PHAXIAM Therapeutics (PHXM), Avalon GloboCare (ALBT), IM Cannabis (IMCC), Heatwurx (PCSA), VivoSim Labs (VIVS), Addex Therapeutics (ADXN), Aptorum Group (APM), BioCardia (BCDA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors HOOKIPA Pharma PHAXIAM Therapeutics Avalon GloboCare IM Cannabis Heatwurx VivoSim Labs Addex Therapeutics Aptorum Group BioCardia TransCode Therapeutics Virax Biolabs Group (NASDAQ:VRAX) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Which has more risk and volatility, VRAX or HOOK? Virax Biolabs Group has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, HOOKIPA Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Is VRAX or HOOK more profitable? Virax Biolabs Group has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Virax Biolabs Group's return on equity of 0.00% beat HOOKIPA Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A HOOKIPA Pharma -785.66%-120.09%-77.14% Which has better earnings and valuation, VRAX or HOOK? Virax Biolabs Group has higher earnings, but lower revenue than HOOKIPA Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$10K269.08-$6.06MN/AN/AHOOKIPA Pharma$9.35M1.21-$43.50M-$5.85-0.16 Do analysts prefer VRAX or HOOK? Virax Biolabs Group presently has a consensus price target of $3.00, suggesting a potential upside of 383.87%. HOOKIPA Pharma has a consensus price target of $4.50, suggesting a potential upside of 383.87%. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00HOOKIPA Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor VRAX or HOOK? In the previous week, Virax Biolabs Group's average media sentiment score of 0.00 equaled HOOKIPA Pharma'saverage media sentiment score. Company Overall Sentiment Virax Biolabs Group Neutral HOOKIPA Pharma Neutral Do institutionals & insiders have more ownership in VRAX or HOOK? 8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryVirax Biolabs Group beats HOOKIPA Pharma on 8 of the 10 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.69M$3.16B$5.79B$10.49BDividend YieldN/A2.36%5.61%4.57%P/E RatioN/A21.17348.8926.87Price / Sales269.08411.81522.55164.30Price / CashN/A44.8326.0131.15Price / Book0.499.8315.536.50Net Income-$6.06M-$52.82M$3.29B$271.42M7 Day Performance-4.05%3.47%200.87%3.69%1 Month Performance-18.95%5.35%184.38%8.07%1 Year Performance-74.59%13.26%325.51%29.65% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group1.6479 of 5 stars$0.62-1.3%$3.00+383.9%-74.3%$2.69M$10K0.005HOOKHOOKIPA Pharma2.4581 of 5 stars$0.90-3.7%$4.50+402.5%-80.5%$10.92M$9.35M-0.15160Positive NewsGap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ALBTAvalon GloboCare0.6623 of 5 stars$2.70+3.8%N/A-12.5%$10.37M$1.33M-0.145Gap UpIMCCIM Cannabis0.2882 of 5 stars$1.96+1.6%N/A-6.7%$10.29M$39.44M-3.63340Gap DownPCSAHeatwurx2.9791 of 5 stars$0.20+0.0%$1.00+398.8%-85.8%$10.10MN/A-0.0920VIVSVivoSim Labs0.263 of 5 stars$3.84-19.7%N/AN/A$9.98M$140K-0.3820ADXNAddex Therapeutics2.267 of 5 stars$9.37-2.6%$30.00+220.2%-8.8%$9.93M$170.62K-27.5630Positive NewsUpcoming EarningsAPMAptorum Group0.2733 of 5 stars$1.85-5.6%N/A-18.2%$9.89MN/A0.0030Analyst UpgradeBCDABioCardia3.3316 of 5 stars$1.70-20.9%$25.00+1,370.6%-54.3%$9.86MN/A-0.9240Analyst ForecastHigh Trading VolumeRNAZTransCode Therapeutics2.062 of 5 stars$11.67+6.6%$280.00+2,299.3%-99.9%$9.69MN/A0.009Positive NewsGap Up Related Companies and Tools Related Companies HOOKIPA Pharma Competitors PHAXIAM Therapeutics Competitors Avalon GloboCare Competitors IM Cannabis Competitors Heatwurx Competitors VivoSim Labs Competitors Addex Therapeutics Competitors Aptorum Group Competitors BioCardia Competitors TransCode Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
